Login to Your Account

Acquisition Likely: Not 'If' but 'When'

ThromboGenics Banks $59M Milestone on EU Approval

By Cormac Sheridan
Staff Writer

Friday, March 15, 2013

ThromboGenics NV is banking a €45 million (US$58.8 million) milestone payment from its partner, Alcon, a unit of Novartis AG, following formal European Union (EU) approval for Jetrea (ocriplasmin) for treating patients with vitreomacular traction (VMT), including those with a macular hole up to 400 microns in diameter.

A second payment of €45 million will follow on the first EU sale of the drug, which are expected to occur in the coming weeks.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription